- Home
- PHGE vs GXAI Comparison
PHGE vs GXAI Comparison
Compare PHGE & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- GXAI
- Stock Information
- Founded
- PHGE 2015
- GXAI 2021
- Country
- PHGE Israel
- GXAI United States
- Employees
- PHGE N/A
- GXAI N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- GXAI
- Sector
- PHGE Health Care
- GXAI
- Exchange
- PHGE Nasdaq
- GXAI Nasdaq
- Market Cap
- PHGE 12.6M
- GXAI 12.0M
- IPO Year
- PHGE N/A
- GXAI 2023
- Fundamental
- Price
- PHGE $0.55
- GXAI $1.80
- Analyst Decision
- PHGE Strong Buy
- GXAI
- Analyst Count
- PHGE 1
- GXAI 0
- Target Price
- PHGE $15.00
- GXAI N/A
- AVG Volume (30 Days)
- PHGE 292.1K
- GXAI 353.1K
- Earning Date
- PHGE 11-13-2025
- GXAI 11-13-2025
- Dividend Yield
- PHGE N/A
- GXAI N/A
- EPS Growth
- PHGE N/A
- GXAI N/A
- EPS
- PHGE N/A
- GXAI N/A
- Revenue
- PHGE N/A
- GXAI $198,711.00
- Revenue This Year
- PHGE N/A
- GXAI N/A
- Revenue Next Year
- PHGE N/A
- GXAI N/A
- P/E Ratio
- PHGE N/A
- GXAI N/A
- Revenue Growth
- PHGE N/A
- GXAI 72158.55
- 52 Week Low
- PHGE $0.34
- GXAI $1.00
- 52 Week High
- PHGE $1.16
- GXAI $7.50
- Technical
- Relative Strength Index (RSI)
- PHGE 56.74
- GXAI 53.99
- Support Level
- PHGE $0.50
- GXAI $1.55
- Resistance Level
- PHGE $0.54
- GXAI $2.00
- Average True Range (ATR)
- PHGE 0.03
- GXAI 0.15
- MACD
- PHGE 0.00
- GXAI -0.00
- Stochastic Oscillator
- PHGE 71.42
- GXAI 53.30
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.